ストックスクリーナーアプリを入手
2.40
0.41%
-0.01
アフターアワーズ：
2.42
0.02
+0.83%
前日終値:
$2.41
開ける：
$2.39
24時間の取引高:
76,137
Relative Volume:
0.52
時価総額：
$3.91M
収益：
$10.48M
当期純損益:
$-37.74M
株価収益率:
-0.1483
EPS:
-16.1846
ネットキャッシュフロー:
$-29.03M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-14.29%
6か月 パフォーマンス:
-88.45%
1年 パフォーマンス:
-97.75%
1日の値動き範囲:
$2.3202
$2.4399
1週間の範囲:
$2.27
$2.51
52週間の値動き範囲:
$2.27
$57.00
Jaguar Health Inc Stock (JAGX) Company Profile
名前
Jaguar Health Inc
セクター
電話
415-371-8300
住所
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
JAGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
2.40 | 3.18M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
Jaguar Health Inc (JAGX) 最新ニュース
What analysts say about Jaguar Health Inc. stockHigh-performance investment picks - Autocar Professional
Is Jaguar Health Inc. a good long term investmentAccelerated profit realization - jammulinksnews.com
Jaguar Health Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com
What drives Jaguar Health Inc. stock priceTremendous return on equity - Autocar Professional
Form DEF 14A Jaguar Health, Inc. For: Aug 19 - StreetInsider
Published on: 2025-07-20 16:31:40 - Autocar Professional
Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC - FinancialContent
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Lancaster Eagle-Gazette
Clinical Trial Launches for First FDA-Approved Dog Diarrhea Treatment, Targeting $6B Pet Health Market - Stock Titan
Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer - ACCESS Newswire
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS In - El Paso Times
Groundbreaking Deal: Peru Grants Access to Sacred Coca Plant for Mental Health Drug Research - Stock Titan
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 36% Hiding - 富途牛牛
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review - ACCESS Newswire
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Lohud
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding - simplywall.st
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient - Worcester Telegram
Breakthrough Treatment Reduces Parenteral Nutrition by 27% in Orphan Disease PatientsNew Clinical Data - Stock Titan
Jaguar Health (JAGX) Announces $3.37M At-The-Market Stock Offering | JAGX SEC FilingForm 424B5 - Stock Titan
Jaguar Health (JAGX) Adopts Cryptocurrency as Treasury Asset | JAGX Stock News - GuruFocus
Jaguar Health considers cryptocurrency for treasury reserves - Investing.com
Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | JAGX Stock News - GuruFocus
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs - Pocono Record
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - The Columbus Dispatch
Jaguar Health extends maturity date for $2.57 million in notes By Investing.com - Investing.com Nigeria
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer - The Holland Sentinel
Jaguar Health reports 25% enrollment in phase 2 MVID study - Investing.com
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Marco Eagle
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts | JAGX Stock News - GuruFocus
Jaguar Health CEO Reveals Near-Term Catalysts at Emerging Growth Conference Tomorrow - Stock Titan
Jaguar Health Inc (JAGX) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
大文字化:
|
ボリューム (24 時間):